Scholars Central

Research articlePublished 2014

Prospective, Longitudinal, Multicenter Observational Study of Long-term Treatment with Intramuscular Interferon β-1a of Patients with Clinically Isolated Syndrome at High Risk of Conversion

Authors: Hernández Miguel Ángel, Prieto, José María, Arnal Carmen, Sánchez Fernando, Izquierdo Guillermo

Journal of Neurology & Neurophysiology

Volume 5 · Issue 2 · Pages 1–6

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Introduction: Early initiation of treatment with intramuscular (IM) interferon (IFN) β-1a in patients with a single demyelinating event suggestive of multiple sclerosis (MS) has been shown to reduce the risk of a second event. This study investigated the characteristics of patients with clinically isolated syndrome (CIS), conversion to clinically definite MS and quality of life (QoL) in clinical practice. Methods: Patients eligible for IM IFNβ-1a for CIS were followed for 4 years (1 visit every 6 months, 9 visits in total). Disease progression was assessed using the Expanded Disability Status Scale (EDSS). The rate of conversion, adverse events and laboratory parameters were reported. Patients were administered QoL questionnaires (Functional Assessment of Multiple Sclerosis [FAMS] and EuroQol 5D [EQ-5D]). Results: Thirty-four patients from 15 Spanish hospitals were included and 18 completed the study. The mean ± SD age of the patients was 32.1 ± 9.08 years and 64% were women. At baseline, the mean EDSS was 0.94 ± 0.85. During follow-up, mean EDSS ranged from 0.89-1.25 and 15 patients (45.5%) converted to CIS. The most common adverse reaction was flu-like syndrome (55%). One patient discontinued treatment due to flu-like syndrome. The mean score on the visual analogue scale of the FAMS and the EQ-5D remained constant throughout the study (p>0.05 with respect to baseline). Conclusions: The conversion rate was higher than in the immediate-treatment arm of CHAMPIONS study, which could be expected due to differences in the patient population and delays in treatment initiation. The added value of the present study lies in the prospective collection of data from the clinical practice in highrisk CIS patients treated with IM IFNβ-1a in Spain. To our knowledge, this is the first study published with these characteristics.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Neurology & Neurophysiology.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Neurology & Neurophysiology
  • SubjectNeuroscience & Neurology
  • BylineArticles whose byline prints “Hernández Miguel Ángel”
  • BylineArticles whose byline prints “Prieto”
  • BylineArticles whose byline prints “José María”
  • BylineArticles whose byline prints “Arnal Carmen”
  • BylineArticles whose byline prints “Sánchez Fernando”
  • BylineArticles whose byline prints “Izquierdo Guillermo”